ALXN1210: Preliminary Phase I/II data

Preliminary data from 13 patients with PNH in a 24-week, open-label, dose-escalation, international Phase I/II trial showed that once-monthly ALXN1210 led to a mean reduction in LDH levels of 85.4% at...